An innovative, internationally operating pharmaceutical company, headquartered in Latvia, part of Northern Europe
Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients.
The company specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
The Grindeks’ Group consists of 5 subsidiary companies in Latvia, Estonia, Russia and Slovakia; representative offices are opened in 12 countries.
Grindeks’ products are exported to 77 countries with export comprising 92,5% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam.
Company’s shares are listed on the Official List of Nasdaq Riga.